|Bid||1.1300 x 2041500|
|Ask||1.1450 x 261700|
|Day's range||1.1300 - 1.1700|
|52-week range||0.6150 - 1.2450|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jan 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.31|
Aroa Biosurgery Limited ( ASX:ARX ) is possibly approaching a major achievement in its business, so we would like to...
Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23. With fewer COVID-19 related disruptions, the Company has entered FY23 with momentum and delivered strong financial results.
New Zealand based soft tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr. Catherine Mohr as a Non-Executive Director to the board.